Interleukin-1 in tumor progression, therapy, and prevention

• Published in: Cancer cell Vol. 39; no. 8; pp. 1023 - 1027
• Main Authors: Garlanda, Cecilia, Mantovani, Alberto
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 09.08.2021
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Humans; Interleukin 1 Receptor Antagonist Protein - pharmacology; Interleukin-1 - genetics; Interleukin-1 - metabolism; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Molecular Targeted Therapy - methods; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Tumor Microenvironment
• ISSN: 1535-6108; 1878-3686; 1878-3686
• DOI: 10.1016/j.ccell.2021.04.011

Interleukin-1 (IL-1) is a key orchestrator of inflammation and plays an important role in tumor progression. Based on preclinical models and human genetic associations, we surmise that targeting IL-1 should be considered in treating selected human tumors as well as in a prevention and/or interception setting. Interleukin-1 (IL-1) is a key orchestrator of inflammation and plays an important role in tumor progression. Based on preclinical models and human genetic associations, we surmise that targeting IL-1 should be considered in treating selected human tumors as well as in a prevention and/or interception setting.